Ajinomoto Bio-Pharma Services
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Ajinomoto Bio-Pharma Services
With pharma sales up 13% in Q3, questions mount about investments in its pipeline to diversify beyond Keytruda and keep the momentum going after its top seller faces biosimilars in 2028.
Plus deals involving OliPass/Vanda, Simcere/Almirall, Sinopharm/Merck & Co., Jiuzhou/Sandoz, Zai Lab/Seagen, Sciwind/SynderK, Hansoh/KiOmed.
Public Company Edition: Direct Biologics, YishengBio and Estrella Biopharma will go public by merging with special purpose acquisition corporations. Also, Vir lands a government contract worth up to $1bn, Idorsia raises CHF164m ($167.4m) in a real estate deal and Adamis reviews alternatives.
Keeping Track: After COVID Delays, US FDA Approvals At Last For Daxxify, Rolvedon (But A CRL For Alvotech)
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
- Contract Research, Toxicology Testing-CRO
- Research, Analytical Equipment & Supplies
- Contract Manufacturing Organization
- Other Names / Subsidiaries
- Althea Technologies, Inc.
- Ajinomoto Pharmaceuticals Co., Ltd.
- EA Pharma Co., Ltd.
- Granules OmniChem Private Limited